This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2014 Jul;32(7):617-9.

doi: 10.1038/nbt.2946.

The premium of a big pharma license deal

Kara E O'Connell¹, Patrik Frei², Kumlesh K Dev³

Affiliations

Affiliations

¹ Drug Development, School of Medicine, Trinity College Dublin, Ireland.
² Venture Valuation AG, Zurich, Switzerland.
³ 1] Drug Development, School of Medicine, Trinity College Dublin, Ireland [2] Venture Valuation AG, Zurich, Switzerland.

PMID: 25004224
DOI: 10.1038/nbt.2946

The premium of a big pharma license deal

Kara E O'Connell et al. Nat Biotechnol. 2014 Jul.

. 2014 Jul;32(7):617-9.

doi: 10.1038/nbt.2946.

Authors

Kara E O'Connell¹, Patrik Frei², Kumlesh K Dev³

Affiliations

¹ Drug Development, School of Medicine, Trinity College Dublin, Ireland.
² Venture Valuation AG, Zurich, Switzerland.
³ 1] Drug Development, School of Medicine, Trinity College Dublin, Ireland [2] Venture Valuation AG, Zurich, Switzerland.

PMID: 25004224
DOI: 10.1038/nbt.2946

No abstract available

PubMed Disclaimer

Similar articles

Goodbye Columbus! New NRDOs forego discovery.
Thiel KA. Thiel KA. Nat Biotechnol. 2004 Sep;22(9):1087-92. doi: 10.1038/nbt0904-1087. Nat Biotechnol. 2004. PMID: 15340473 No abstract available.
Value creation and sharing among universities, biotechnology and pharma.
Edwards MG, Murray F, Yu R. Edwards MG, et al. Nat Biotechnol. 2003 Jun;21(6):618-24. doi: 10.1038/nbt0603-618. Nat Biotechnol. 2003. PMID: 12776145 No abstract available.
More drugs, less protection.
[No authors listed] [No authors listed] Nature. 2002 Sep 19;419(6904):233. doi: 10.1038/419233a. Nature. 2002. PMID: 12239521 No abstract available.
Macro trends in pharmaceutical innovation.
Cohen FJ. Cohen FJ. Nat Rev Drug Discov. 2005 Jan;4(1):78-84. doi: 10.1038/nrd1610. Nat Rev Drug Discov. 2005. PMID: 15688075 Review.
[Technology transfer between academic laboratories and industrial laboratories: licensing].
Salauze D. Salauze D. Ann Pharm Fr. 2010 Sep;68(5):301-5. doi: 10.1016/j.pharma.2010.04.003. Epub 2010 May 31. Ann Pharm Fr. 2010. PMID: 20850001 Review. French.

See all similar articles

Cited by

Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries.
Bhatnagar B, Dörfler V, MacBryde J. Bhatnagar B, et al. J Technol Transf. 2022 Aug 18:1-45. doi: 10.1007/s10961-022-09958-6. Online ahead of print. J Technol Transf. 2022. PMID: 35996639 Free PMC article.

References

1. Nat Biotechnol. 2004 Aug;22(8):1049-51 - PubMed
1. Nat Rev Drug Discov. 2009 Jun;8(6):443 - PubMed
1. Drug Discov Today. 2013 Nov;18(21-22):1027-9 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information